Scientists have developed a blood test capable of predicting certain lung cancers several years before an official diagnosis [1].
This development is significant because early detection of lung cancer typically improves treatment outcomes. By identifying the disease before symptoms manifest, medical providers may be able to intervene while the cancer is more treatable.
The test works by identifying specific protein signatures in the blood. While reports on the exact composition vary, some data suggests the use of a 14-protein signature to identify high-risk individuals [2]. Other reports regarding a specific test called LungCanSeek—which was announced in a press release on Oct. 1, 2025 [4]—said the method utilizes four protein markers [3].
According to some reports, the test can predict the onset of the disease up to five years before a clinical diagnosis [2]. This window of time allows for more aggressive monitoring and preventative care for those identified as high-risk.
Reports on the origin of the technology are inconsistent. Some sources associate the breakthrough with researchers reported by CTV News in Toronto [1], while other reports said Chinese scientists developed a handheld device to detect the cancer from a single drop of blood [5].
The research team aims to move these screenings into broader clinical use to reduce mortality rates. Because lung cancer is often detected in late stages, a blood-based screening tool could replace or supplement more invasive diagnostic procedures.
“The test can predict the onset of the disease up to five years before a clinical diagnosis.”
The transition from imaging-based screening to protein-signature blood tests represents a shift toward liquid biopsies. If validated across larger populations, this technology could allow for mass screening of high-risk groups—such as long-term smokers—without the immediate need for expensive radiation-heavy CT scans, potentially catching malignancies in stages where surgical cure rates are significantly higher.
